Certified by Founder Lodge
Sitryx
United Kingdom - Oxford, England
START UP
1 Disclosed Funding Rounds $39,500,000
0 Participating Investments
-
Founded date
2018
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation.
The company
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| September, 28 ,2023 | Unknown | $39,500,000 |
Oxford Science Enterprises
Eli Lilly and Company
SV Health Investors
Sofinnova Partners
Longwood Fund
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
CRESS | $234,000 | (Feb 21, 2025)
Reverb Therapeutics | $21,000,000 | (Feb 21, 2025)
Safe Intelligence | $5,253,443 | (Feb 21, 2025)
EnPlusOne Biosciences | $10,000,000 | (Feb 21, 2025)
OpenEvidence | Undisclosed Amount | (Feb 21, 2025)
